DCM
FOLD

Delpha Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Delpha Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-3,399
Closed -$49K – 511
2017
Q4 		$49K Buy
+3,399
New +$46.7K 0.05% 318

Other funds holding FOLD

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Delpha Capital Management's FOLD Position: Q1 2018 in Review

Delpha Capital Management sold out of Amicus Therapeutics (FOLD) in Q1 2018, closing a stake of 3,399 shares — an estimated $49K sold.

Delpha Capital Management first reported a position in FOLD in Q4 2017 and held it in 1 quarter. The position peaked at $49K in Q4 2017. 203 funds tracked by Wall St. Rank hold FOLD as of Q1 2018.

  • Delpha Capital Management reported no remaining Amicus Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 3,399 Amicus Therapeutics shares in Q1 2018, an estimated $49K.
  • Delpha Capital Management first reported a position in Amicus Therapeutics in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Amicus Therapeutics position peaked at $49K in Q4 2017.
  • 203 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.